1,057 reports of this reaction
10.7% of all ATOGEPANT reports
#1 most reported adverse reaction
MIGRAINE is the #1 most commonly reported adverse reaction for ATOGEPANT, manufactured by AbbVie Inc.. There are 1,057 FDA adverse event reports linking ATOGEPANT to MIGRAINE. This represents approximately 10.7% of all 9,899 adverse event reports for this drug.
Patients taking ATOGEPANT who experience migraine should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
MIGRAINE is a frequently reported adverse event for ATOGEPANT, accounting for a significant proportion of all reports.
In addition to migraine, the following adverse reactions have been reported for ATOGEPANT:
The following drugs have also been linked to migraine in FDA adverse event reports:
MIGRAINE has been reported as an adverse event in 1,057 FDA reports for ATOGEPANT. This does not prove causation, but indicates an association observed in post-market surveillance data.
MIGRAINE accounts for approximately 10.7% of all adverse event reports for ATOGEPANT, making it one of the most commonly reported side effect.
If you experience migraine while taking ATOGEPANT, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.